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Objective: To compare two protocols for intrapartum antibiotic prophylaxis (IAP) against neonatal group B
streptococcal (GBS) sepsis, with respect to staff compliance, in a prospective cohort study in the obstetric units
of a community hospital (A) and a university teaching hospital (B).
Methods: Cohortscomprised about 500 women attendingantenatal clinics at each hospital (total 1096). Women
identifiedasGBS carriersat26–32 weeks’ gestationandthosewho had intrapartumclinicalriskfactors(CRF)were
eligible for IAP. Compliance was defined as the proportion of women eligible for IAP who received it according
toprotocol–asdeterminedbyauditofcaserecords–andcomparedbetweenhospitalsandaccordingtoindication.
Results: Overall, 39% of women were eligible for IAP. Indications were GBS carriage alone (21%), CRF alone
(13%) and both (5%). Compliance was similar for GBS carriers at both hospitals: 78% at Hospital A and 76% at
HospitalB.However,becauseof the poorpredictivevalueofscreeningbefore32 weeks,only65% of intrapartum
GBS carriers actually received IAP. For women with CRF only, compliance was significantly lower at Hospital B
than Hospital A (56 vs. 75%; p = 0.03).
Conclusions: According to currently recommended protocols, about one-third of healthy women are eligible for
intrapartumantibiotics to prevent neonatal GBS sepsis. In practice, antibiotics are often used inefficiently because
of poor compliance with protocols and poor predictive values of selection criteria. Better implementation
strategies should improve compliance, but GBS vaccines are needed to replace prophylactic antibiotic use, with
its associated disadvantages.
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Intrapartum antibiotic prophylaxis (LAP) can
reduce vertical transmission of group B strepto-
coccus (GBS) and prevent most cases of neonatal
GBS sepsis1. However, the best way to identify
women whose infants are at risk is controversial.
When this study was planned, routine antenatal
screening at 28–32weeks’ gestation and IAP forall
carriers wasestablished inafewAustralianobstetric
hospitals2–4. An alternative strategy based on
clinical risk factors (CRF) during labor had been
proposed5 but not evaluated. Subsequently,
consensus guidelines for prevention of neonatal
GBS sepsis were published in the USA6, but have
been implemented inconsistently elsewhere7,8.
The effectiveness of any strategy depends on
compliance with protocols. Previous studies have
shown variation in rates of compliance with IAP
protocols of 65–85%, but there has been no direct
comparison of compliance with different proto-
cols9–11. The aim of this study was to compare
two IAP protocols, in a community hospital (A)
and a university teaching hospital (B), to assess
compliance and factors affecting it.
METHODS
Study design
On the basis of a theoretical comparison of four
strategies5, we chose, for comparison, the two
that had been judged to provide the best balance
between the proportions of preventable cases of
neonatal GBS sepsis and of women given anti-
biotics. We believed that randomization of
strategies would be impractical and inclusion of
an untreated control group unethical. Instead,
we implemented both strategies, concurrently,
and compared them. The two strategies were:
(A) IAP for all women identified as GBS carriers
by antenatal screening at 26–32 weeks’
gestation; and
(B) IAP for all women in whom one or more
CRF was present on admission to the
delivery suite or developed at any time up to
30 minutes before anticipated delivery. CRF
for perinatal sepsis were defined as follows: a
previous infant with GBS sepsis or GBS
urinary tract infection; preterm labour (< 37
weeks’ gestation); prolonged rupture of
membranes (PROM, > 18 hours); intra-
partum fever (see below).
IAP consisted of ampicillin, 1 g intravenously
every 6 hours (or erythromycin 500 mg intra-
venously every 6 hours for women with suspected
penicillin allergy) until delivery.
The study plan was to recruit and follow to
delivery, cohorts of about 500 women at each of
two hospitals in western Sydney. Cohort sizes
were determined on the basis of estimated rates of
GBS carriage and risk factors and to achieve con-
fidence intervals within ± 5%.
Hospitals and protocols
The obstetric unit at Hospital A delivers approxi-
mately 2600 babies per annum and has a special
care (level 2) nursery. An IAP protocol based on
strategy B was implemented in 1996, with in-
service training of staff. The definition of maternal
fever was a temperature > 37.5°C. Results of
audits of patient records, conducted before and
afterthecohortstudytoassess compliancewiththis
risk-factor-based protocol, have been reported
separately12.
A cohort of approximately 500 women was
recruited at Hospital A duringthe first 6monthsof
1997. Antenatal clinic staff approached consecu-
tive women at their first antenatal visits, explained
the nature of the study and asked them to partici-
pate. Demographic data from those who agreed
were recorded immediately, and vaginal and anal
swabs were collected at 26–32 weeks’ gestation
and repeated during labor. Women in the cohort
were eligible for IAP if they had been identified
as GBS carriers, and/or if one or more CRF
was present on admission to the delivery suite or
developed at any time until 30 minutes before
delivery. Research nurses were responsible for
in-service training of antenatal clinic and labor
ward staff. Otherwise, protocol implementation
was the responsibility of hospital staff.
Hospital B is a tertiary referral centre with an
obstetric unit that manages approximately 4300
deliveries per annum; the hospital has both
neonatal intensive care (level 3) and special care
nurseries. Thestudy protocolwas generally similar
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protocol was introduced in early 1998, without
specific in-service staff training; according to this
protocol,maternal fever was defined as a tempera-
ture of 38°C. As for Hospital A, audits of patient
records were done before and after recruitment of
the study cohort to assess compliance with the
risk-factor-based protocol alone12.
Recruitment of the cohort occurred during
an 8-month period in 1998–9. Research staff
recruited women and, consecutively, obtained
informed consent and collected demographic
data and swabs from those who agreed to partici-
pate, at the same visit (at 26–32 weeks’ gestation).
Eligibility criteria for IAP at Hospital B were the
same as for Hospital A except that maternal fever
was defined as 38°C, according to protocol.
Compliance with delivery suite protocols for
each hospital was assessed by review of medical
records and defined as the proportion of women
fulfilling the criteria for IAP, according to the
corresponding protocol, who were given at least
one dose of an appropriate antibiotic at least 30
minutes before delivery.
Microbiology
Cultures from both hospitalswere processed at the
same laboratory. Full details of microbiological
methods and results have been reported sep-
arately13. Briefly, all swabs were plated onto horse
blood agar and GBS selective media directly and
then placed in enrichment broth for overnight
incubation before subculture onto agar. GBS
carriers were defined as women from whom GBS
was isolated from either vaginal or anal swab or
both, by direct plating and/or after overnight
enrichment culture. The medical records of GBS
carriers were marked with a prominent coloured
sticker.
Neonatal outcome
Infants admitted to special or intensive care
nurseries, witha diagnosisofsuspected sepsis, were
classified, after record review, as having:
(i) no sepsis;
(ii) clinical sepsis (negative cultures but clinical,
radiological and/or other laboratory evidence
of sepsis; response to antibiotic therapy); or
(iii) bacteriologically confirmed sepsis (significant
isolate from blood or other sterile site
culture).
Statistical analysis
DatawereenteredintoaMicrosoftAccessdatabase
and converted to an SAS dataset for analysis using
SAS version 6.12 for Windows and Epi Info
version 6.04b. Pearson’s c2 test or Fisher’s exact
test where used, as appropriate, to compare non-
parametric data. Positive and negative predictive
(PPV, NPV) values and confidence intervals (CI)
were calculated in Epi Info.
Ethical approval
Ethical approval for the study was granted by the
Western Sydney Area Health Service Human
Research Ethics Committee.
RESULTS
GBS carriage rates and CRF are summarized in
Table 1. The two cohorts comprised 1096
women who had full sets of antenatal and
intrapartum GBS culture results. Antenatal and
intrapartum GBS carriage rates were similar (27
and 24%, respectively) and did not differ signifi-
cantly between hospitals. The PPV and NPV of
antenatal screening for intrapartum GBS carriage
were 69 (95% CI, 64–74) and 92% (95% CI
90–94), respectively. One or more CRF were
identified during labor in 18% of women, most of
whom (81%; 95% CI 75–86) had only one. CRF
were presentin similar proportionsofGBS carriers
and non-carriers.
Indications for and compliance with protocols
for IAP
According to labor ward protocols, 429 of 1096
(39%; 95% CI, 36–42) women were eligible for
IAP (Table 2). Labor ward records showed that
361 women were given antibiotics during labor;
47 were given antibiotics for another indication
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dosewasgiven less than30 minutesbeforedelivery
and were excluded from analysis. Thus, 314
women, or 73% (95% CI, 69–77) of those eligible
– 77% at Hospital A and 69% at Hospital B – were
given IAP according to one or both protocols
(Table 2). Most patients had only one CRF. The
onlysignificantdifferencebetweenhospitalswasin
women with a single CRF, who were not GBS
carriers (Table 3). Compliance varied significantly
according to individual CRF. Compliance was
highest when the CRF was fever and lowest when
it was preterm birth.It was higherforpatientswho
had more than oneCRF or were also GBS carriers
than for patientswith a single risk factor who were
non-carriers. Two or more CRF, or CRF plus
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Hospital A: n = 5813
n (%; 95% CI)
Hospital B: n = 5153
n (%; 95% CI)
Total: n = 1096
n (%; 95% CI)
Antenatal  GBS culture positive1
Intrapartum GBS culture positive1
History of GBS-infected infant2
GBS bacteriuria
Premature labour (< 37 weeks)
PROM (> 18 hours)
Intrapartum fever
Any risk factor
Single risk factor
Two or more risk factors
Risk factors in
IP GBS carriers
IP GBS non-carriers
151 (26; 22–30)
148 (25.5; 22–29)
0/355
4 (0.7)
27 (4.7)
61 (10.5)
20/563 (3.6)4
95 (16)
79 (14)
16 (2.8)
25/148 (17)
70/433 (16)
140 (27; 23–31)
120 (23; 20–27)
2/265 (0.75)
3 (0.6)
24 (4/7)
71 (14)
28/479 (5.8)4
105 (20)
82 (15.5)
23 (4.5)
31/120 (26)5
74/395 (19)5
291 (27; 24–29)
268 (24; 22–27)
2/610 (0.033; 0.004–0.12)
7 (0.064; 0.026–0.13)
51 (4.7; 3.5–6.1)
132 (12; 10–14)
48/1042 (4.6; 3.4–6.1)
200 (18; 16–20.5)
161 (15; 13–17)
39 (3.6; 2.6–4.8)
56/268 (21; 16–26)
144/828 (17; 15–20)
1Sensitivity, specificity, positive and negative predictive values of positive antenatal screening for intrapartum carriage were 76.5, 88.4,
69.3 and 92.1%, respectively;
2multiparous women only;
3there were no significant differences betwen proportions at Hospitals A and B;
4the different definitions of fever used at each hospital (see text) were used for calculation of incidence of risk factors and compliance with
intrapartum antibiotic prophylaxis; difference not significant;
5differences between GBS carriers and non-carriers not significant;
IP, intrapartum; GBS, group B streptococcus; PROM, premature rupture of membranes
Table 1 Indications for intrapartum antibiotic prophylaxis: antenatal and intrapartum GBS carriage rates and clinical
risk factors
Hospital A Hospital B
Eligible for IAP1
(% of cohort)
Given IAP as per protocol
(% compliance; 95% CI)2,3
Eligible for IAP1
(% of cohort)
Given IAP as per protocol
(% compliance; 95% CI)2,3
All AN GBS carriage
AN GBS carriage alone
AN GBS carriage and RF
All RF
RF alone4
Total (all indications)
151 (26)
123 (21)
28 (4.8)
95 (16)
67 (11.5)
218 (37.5)
118 (78; 72–85)
96 (78; 71–85)
22 (79; 59–92)
73 (77; 67–85)
50 (75; 62.5–84.5)4
168 (77; 71.5–83)
138 (27)
108 (21)
30 (5.9)
103 (20)
73 (14)
211 (42)
105 (76; 69–83)
78 (72; 64–81)
27 (90; 74–98)
68 (66; 57–75)
41 (56; 44–68)4
146 (69; 63–75)
1According to either of two labor ward protocols, using original definitions of maternal fever (see text for details). Two women at Hospital
B were admitted to delivery suite less than 30 minutes before delivery were excluded;
2see text for details of protocols and exclusions;
3percentage of women eligible for IAP who received it according to protocol;
4significant difference in compliance between Hospital A and
Hospital B (p = 0.03). All other differences not significant; AN, antenatal; GBS, group B streptococcus; RF, risk factors; IAP, intrapartum
antibiotic prophylaxis
Table 2 Indications for intrapartum antibiotic administration and compliance with labor ward protocols for
intrapartum antibiotic prophylaxisGBS carriage, were present in 89 of 198 women
(45%; 95% CI, 38–52) with CRF, or 8.1% (95%
CI, 6.6–6.9) of all women.
Intrapartum culture results indicated that IAP
had been given according to protocol to 89 of 148
women (60%; 95% CI, 52–68) at Hospital A and
84 of 120 (70%; 95%CI, 62–78) at Hospital B who
were carryingGBS at delivery. On theotherhand,
29 of96women (30%; 95% CI, 21–40) at Hospital
A and 25 of 83 (30%; 95% CI, 20–41) at Hospital
B, who were given IAP because of antenatal GBS
carriage alone, were culture negative at delivery.
Neonatal outcome
Similar proportionsofinfantsatbothhospitals(8%)
were investigated forsepsis and94% ofthem (81 of
86) were treated empirically, with antibiotics.
These infants included 49 of 360 (14%; 95% CI,
10–17) whose mothers had been, and 32 of 754
(4.2%; 95% CI, 2.9–5.9) whose mothers had not
been, given IAP (p < 0.001). Seventeen infants
(1.6%) had clinical evidence of sepsis but negative
cultures and all recovered without sequelae;
the incidence was significantly higher at Hospital
B than Hospital A (Table 4). Ten of 17 mothers
of infants with clinical sepsis were eligible for
IAP and seven had been given it according to
protocol.
DISCUSSION
Theproportionofcases ofneonatalGBS sepsis that
can be prevented by IAP depends on accurate
identification of intrapartum GBS carriage and
CRF, their respective predictive values and the
effectiveness of IAP. Any of several recommended
strategies5 should be cost-effective14, although
nonecan preventallcases. In atheoreticalcompar-
ison, we estimated that strategies A and B would
prevent approximately 80 and 70%, respectively,
of cases of GBS sepsis and that 20 and 10% of
women, respectively, would be eligible for IAP5.
We rejected a third strategy involving late ante-
natal screening (at 37 weeks) and IAP for carriers
and women with CRF, whose GBS carrier status
was unknown, because we estimated that it
would involve giving IAP to a very high propor-
tion of healthy women (23.5%). The present study
showed that we significantly underestimated the
proportions of women who would be eligible for
IAP according to any of these strategies.
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Indication
Hospital A Hospital B All
Eligible
for IAP1
Compliance2
(%; 95% CI)
Eligible
for IAP1
Compliance2
(%; 95% CI)
Eligible
for IAP1
Compliance
(%)
Preterm delivery only
PROM only
Maternal fever3 only
GBS bacteriuria
Any single RF4
AN GBS carriers
Non GBS carriers5
Two or more RF
19
45
12
3
79
25
52
16
7 (37; 16–62)
37 (82; 68–92)
12 (100; 73.5–100)
1
57 (72; 61–82)
20 (80; 59–93)
37 (71; 57–83)
16 (100; 79–100)
13
49
15
3
80
25
55
23
4 (31; 9–61)
27 (55; 40–69)
13 (87; 59.5–98)
2
46 (57.5; 46–68.5)
22 (88; 69–97.5)6
24 (44; 30–58)6
22 (96; 78–99.9)
32
94
27
6
159
50
107
39
11 (34)7
64 (68)7
25 (93)7
3 (50)
103 (65)8
42 (84)9
61 (57)9
38 (97)8
1According to the defined labor ward protocols for each Hospital (see text for details);
2percentage of women who were eligible for IAP and
received it according to protocol;
3maternal fever defined by hospital protocols (> 37.5°C Hospital A; > 38°C Hospital B);
4difference
between Hospital A and Hospital B not statistically significant (p= 0.08);
5significant difference between Hospital A and Hospital B
(p = 0.01);
6difference between GBS carriers and non-carriers with single RF at Hospital B was significant (p < 0.0001);
7difference in
compliance between individual RF was highly significant (p = 0.00001);
8difference in compliance between a single RF and two or more was
significant (p = 0.001);
9difference in compliance between GBS carriers and non-carriers with single RF was significant (p = 0.002); AN,
antenatal; PROM, prolongued rupture of membrane; RF, risk factors; GBS, group B streptococcus; IAP, intrapartum antibiotic prophylaxis
Table 3 Compliance with intrapartum antibiotic prophylaxis protocols at Hospitals A and B for women with various
risk factorsMaternal GBS carriage is a crude predictor of
neonatal sepsis, no matter how accurately it is
identified. GBS is part of the normal vaginal flora
and fewer than 1% of the infants of carriers will
developsepsis even withoutIAP.Theincidenceof
GBS carriage in this study was higher (27%) than
previously described in Australia2–4, because we
used more sensitive methods to detect it.
However, the PPV of antenatal screening before
32 weeks’ gestation, for intrapartum GBS carriage,
was poor. Added to only fair compliance with
protocols, this further limited the benefit of IAP
for GBS carriers. A significant proportion of
intrapartum carriers did not receive IAP and
some who received it were not identified as carri-
ers at the time of delivery. In this study, we
included only women whose GBS carrier status
was known. In practice compliance with ante-
natal GBS screening protocols is likely to be only
70–80%3,15.Thiswouldfurtherreducethepropor-
tion of intrapartum carriers who would receive
IAP using this protocol.
Screening at 35–37 weeks’ gestation, as recom-
mended intheCentersforDisease Control(CDC)
consensus guidelines6, would predict intrapartum
carriage better16. This strategy involves adminis-
tration of IAP to GBS carriers and women with
CRF whose culture results are unavailable which,
in our population, would be up to 35% of
women (GBS carriers 27%; preterm/prescreening
deliveries 5%; intrapartum fever 2–3%). An alter-
native strategy which, until recently, was
recommended by the CDC6 is similar to our
protocol B. Based on our study, it would involve
giving IAP to about 19% of women in our
population (18% with CRF and 1% with history
of past GBS infection).
Recently, CDC has published revised guide-
lines, recommending a single strategy for pre-
vention, based on universal prenatal screening for
vaginal and/or rectal GBS colonisation17. This
revision was based on the results of a retrospective
cohort study, which showed a significantly lower
rate of perinatal GBS sepsis in infants of women
giving IAP on the basis of GBS screening, than in
infants of women managed on the basis of
risk factors (relative risk, 0.48; 95% CI,
0.37–0.63)18. In contrast to our results, the antici-
pated overall rate of intrapartum antibiotic use,
based on the CDC study, was similar for both
preventive strategies (31 and 29%, compared with
35 and 19%, respectively, in our study). These
differences are apparently due to a higher inci-
dence of risk factors in the USA compared with
Australia and failure to account for women given
IAP during preterm labour before results of
screening are available.
The finding that a strategy based on screening
could prevent more cases of GBS sepsis than one
based on risk factors alone is notsurprising. A risk-
factor-based protocol cannot, by definition, pre-
vent sepsis in infants whose mothers have no risk
factors. Based on a case–control study of neonatal
GBS sepsis, Rosenstein and co-workers estimated
that full compliance with a protocol based on late
antenatal screening (as above) should prevent 78%
of cases of GBS sepsis9. By comparison, it was
estimated thataprotocolbasedonrisk factorsalone
should prevent a similar proportion of cases in
prematureinfants,inwhommostdeathsoccur,but
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Hospital A (n = 587)
n (%, 95% CI)
Hospital B (n = 527)
n (%, 95% CI)
Suspected sepsis
Clinically confirmed sepsis1
Mothers given/eligible for IAP (indications)
Mother not given IAP (indication if any)
51 (8.7; 6.5–11.3)
3 (0.5; 0.104–1.48)3
1/3 (GBS carriage, 1; single RF, 2)
2 (single RF, 2)
35 (6.6; 4.7–9.1)
14 (2.7; 1.28–4)3
6/7 (GBS carriage, 4; GBS carriage
and RF, 2; single RF, 1)
8 (GBS carriage, 1)
1Clinical hematological or radiological evidence of sepsis and response to antibiotic therapy but negative cultures;
295% confidence interval
calculated by exact method;
3difference between Hospital A and B significant (p = 0.005, Fisher’s exact test); RF, risk factors (see text for
details); GBS carriage, positive antenatal vaginal and/or rectal swabs; IAP, intrapartum antibiotic prophylaxis; GBS, group B streptococcus
Table 4 Infants of women in two cohorts with suspected sepsisonly30% ofcases in full-term infants,inwhomthe
incidence and mortality are very low9. In a more
recent study it was estimated that 60% of cases,
overall, could be prevented using a risk-factor-
based study19. A recent review of cases of neonatal
GBS septicaemia at Hospital B over an 8-year
period showed that a poor outcome correlated
withCRF.Fourof20infantsofwomenwithCRF
died, whereas all 19 infants of women who had no
intrapartum CRF recovered without sequelae13.
Non-compliance with IAP protocols is often
blamed for the occurrence of neonatal GBS
sepsis20, but there has been little evaluation of this
claim21. Previous studies have shown compliance
rates varying from around 80%10,22 for a protocol
based mainly on GBS carriage, to 65% for a CRF-
based protocol11. However, there has been no
previous direct comparison of strategies. In the
present study,therate of compliancewith IAP,for
women with CRF only, was similar to that for
GBS carriers at one hospital, but significantly
lower at the other. This probably reflects differ-
ences in protocol implementation. At Hospital A,
the CRF-based protocol was implemented as part
of the study, with specific in-service training of
labour ward staff whereas, at Hospital B, a similar
protocol had been already implemented when the
study began. Poor compliance with IAP for
women with CRF at Hospital B was associated
with, but probably not the cause of, a significantly
higher incidence of clinically diagnosed neonatal
sepsis, noneofwhichwasshowntobeduetoGBS.
Seven of 14 mothers of affected infants were
eligible for IAP and six received it according
to protocol.
The fact that compliance rates were similar for
both protocols in one hospital suggests that better
implementation may have improved compliance
with the CRF protocolat the other. Nevertheless,
despite the best efforts of the research team, com-
plianceat bothhospitalswasonlyfair.Thiswasnot
due to confusion caused by two protocols being
used simultaneously. Chart audits before and after
the cohort studies showed that compliance with
the CRF-based protocol, at both hospitals, was
lower before than during the cohort study. How-
ever, despite improvement, especially at Hospital
B, it reverted to previously low levels at the end of
the cohort study; 65% at Hospital A and 50% at
Hospital B12. Apparently, the staff at Hospital B
were more aware of GBS carriage than CRF as
an indication for IAP, despite its poor PPV. This
illustrates the importance of staff education,
ownership of and responsibility for protocols by
unit staff themselves. Changes in the design of
record sheets to highlight CRF, ongoing
in-service training of staff, standing orders
for antibiotic therapy to avoid delays and
periodic evaluation of compliance, with feed-
back to staff, are among strategies we have
identified to improve and maintain high rates of
compliance.
Thereislittlehigh-qualityevidence23tosupport
the use of any IAP strategy. Randomized, con-
trolled trials to compare efficacies of different
strategies wouldrequireimpracticablylargesample
sizes and use of an untreated control group would
not be unethical. Case audits as used in this study,
to identify failed prophylaxis or assess protocol
compliance, are useful, but not ideal methods
of comparison and other factors must also be
considered.
The higher proportion of potentially prevent-
able cases of sepsis in full-term infants, when GBS
carriage late in pregnancy and selected CRF are
the criteria for IAP, compared with CRF
only6,11, must beweighed against thedisadvantages
of giving antibiotics to nearly twice as many
women – as would be indicated in Australia, based
on our data13. Penicillin anaphylaxis is rare
(1–5/10 000)24, but can be fatal for mother or
infant25 and less severe allergic reactions are
common (5–10%). An increase in the proportion
of cases of neonatal sepsis due to penicillin/
ampicillin-resistant bacteria, associated with
increased use ofIAP,has been reported26–29. In our
study, infants of women given IAP were signifi-
cantly more likely than other infants to be
given empirical antibiotic therapy, although few
had objective evidence of sepsis. Separation of
otherwise normal infants from their mothers and
potential complications of intravenous therapy
are among the costs of IAP13,30. Antibiotic
therapy in utero or in the first few days of life
could affect establishment of the infant’s gut flora
and ultimately increase the overall prevalence
of antibiotic resistance among the normal flora,
including GBS28,31.
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neonatalGBS sepsis isideal.IAPcanpreventahigh
proportionof cases if the most sensitive criteria are
used but only at the expense of giving antibiotics,
unnecessarily, to large numbers of healthy women
and their infants. The limited efficiency of IAP is
reduced further by poor compliance, unless great
attention is paid to implementation and main-
tenance of protocols. More efficient methods
of prevention are needed. Further significant
reduction in the incidence of neonatal GBS sepsis
is unlikely to be achieved until a conjugate GBS
vaccine is available.
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